Pieris Pharmaceuticals, Inc. (OTCQB: PIRS), a biotechnology company advancing its patented and proprietary Anticalin® biotherapeutic technologies, announced today that Jean-Pierre Bizzari, M.D., has joined the Company's Board bringing the total number of directors to six.

Dr. Bizzari was the Executive Vice President, Group Head, Clinical Oncology Development at Celgene Corporation. Since joining Celgene in 2008, he directed the development and approval of a number of leading oncology products including REVLIMID®, VIDAZA®, ISTODAX®, and ABRAXANE®.

One of the region’s biggest real estate investors just plunked down more money into the South of Market neighborhood that will soon give rise to a swarm of new offices for technology companies.

Alexandria Real Estate Equities (NYSE: ARE) – which has specialized in life sciences and now is building offices for Uber in Mission Bay and Stripe in SoMa– will team up on a joint venture with TMG Partners on the already-approved 505 Brannan St. TMG made the announcement Tuesday morning.

Baxter International is shelling out $900 million on Sigma-Tau’s Oncaspar (pegaspargase) product portfolio, in a move designed to strengthen its commercial foothold in the global oncology market.   Oncaspar is a first-line biologic used as part of a multi-agent chemotherapy regimen to treat the blood cancer acute lymphoblastic leukaemia (ALL), currently pulling in sales of around $100 million a year.

Baxter International Inc. (NYSE:BAX) announced it has signed a definitive agreement to acquire the Oncaspar® (pegaspargase) product portfolio from Sigma-Tau Finanziaria S.p.A. The acquisition further accelerates the innovation capabilities and the commercial presence of Baxter BioScience in growing oncology markets for rare and orphan diseases. The company gains the leading marketed biologic treatment Oncaspar, the investigational biologic calaspargase pegol, and an established oncology infrastructure with clinical and sales resources. The Oncaspar transaction is expected to close in the third quarter. By mid-year, Baxter expects to establish the BioScience business as a separate, publicly traded, innovation-oriented biopharmaceutical company, Baxalta Incorporated.

Congratulations to all the winners in the third InvestMaryland Challenge. All four will receive a $100,000 top prize from the Department of Business and Economic Development. Check out the rest of the prize winners in the list below, and an explanation of all the different prizes provided by sponsors and partners here.

The Institute for Life Science Entrepreneurship (ILSE), a non-profit translational science research integrator, accelerator and incubator, and ATCC, the premier global biological materials resource and standards organization, announced today a collaboration to establish The ATCC Center for Translational Microbiology at ILSE (the “Center”).

The focus of the Center will be on key challenges identified by both ATCC and ILSE in current translational microbiology, including antimicrobial resistance, synthetic biology, microbial bioinformatics and the microbiome. Research laboratories and staff will be located at ILSE facilities within the state-of-the-art New Jersey Center for Science, Technology & Mathematics (NJCSTM) building at Kean University. Kean University is a founding member of ILSE.

Welcome to the National Heart, Lung, and Blood Institute (NHLBI) Strategic Visioning Forum. The Institute is gathering ideas for the most compelling scientific priorities in the four NHLBI Strategic Goals to address over the next decade.

Your opportunity to submit initial ideas to help the NHLBI Strategic Visioning process will close on May 15. Click on Submit a New Question or Challenge and don’t miss your chance to share your voice!

The Biotechnology Industry Organization (BIO), the National Science Foundation (NSF) and the National Institutes of Health (NIH) today announced an agreement to feature Small Business Innovation Research (SBIR) funded early-stage biomedical companies in an expanded Innovation Zone at the 2015 BIO International Convention®. The Innovation Zone companies, focused on drug discovery, diagnostics and other therapeutic platform technologies, will have dedicated exhibit space and participate in BIO One-on-One Partnering™. Select companies will make 15-minute company presentations in the BIO Business Forum. The Innovation Zone will also feature six universities funded under the prestigious NSF Accelerating Innovation Research Program (AIR). This select group will demonstrate advanced biomedical prototypes that are very close to commercialization stage.

UNC and pharmaceuticals giant GlaxoSmithKline are joining forces to try developing a cure for HIV/AIDS, with the British company pledging a five-year, $20 million contribution to the effort.

GSK is also chipping in a 10-person research team, to work with faculty members, post-doctoral fellows and graduate students attached to four different labs in UNC’s medical and pharmacy schools.

I’ve known Edmund Pendleton from the University of Maryland as the Director of the D.C. National Science Foundation (NSF) I-Corps Node (a collaboration among the University of Maryland, Virginia Tech, George Washington, and Johns Hopkins). But it wasn’t until seeing him lead the first I-Corps class at the National Institutes of Health that I realized Edmund could teach my class better than I can. After seeing the results of 500+ teams through the I-Corps, the NSF now offers all teams who’ve received government funding to start a company an introduction to building a Lean Startup.

Sucampo Pharmaceuticals, Inc., a global pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for cobiprostone, a locally acting chloride channel activator, for the prevention of oral mucositis. The FDA has also accepted the company's Investigational New Drug (IND) application to initiate a phase 2 clinical trial of cobiprostone for the prevention of oral mucositis in patients suffering with head and neck cancer receiving concurrent radiation and chemotherapy.

Physicians are not only becoming more proficient with EHRs, they are using their systems for more than just reference. That’s the conclusion of a new Accenture survey of more than 2,600 doctors in Australia, Brazil, England, Norway, Singapore and the U.S.

Interoperability is growing as well, albeit slowly. In 2015, for the first time, a majority of U.S. physicians surveyed by Accenture (51 percent) said they “routinely” access patient data from outside their organizations, up just slightly from 45 percent in 2012.

Of all the rumors ever to swirl around the world’s most valuable company, this may be the first that could involve spitting in a plastic cup.

Apple is collaborating with U.S. researchers to help launch apps that would offer some iPhone owners the chance to get their DNA tested, many of them for the first time, according to people familiar with the plans.

Montgomery College offers Summer 2015 classes designed to meetyour entrepreneurial needs in support of your business ideas.

For Aspiring Entrepreneurs:

The Intentional Entrepreneur:

This one day class helps you identify your entrepreneurial skills and abilities, and addresses any concerns you may have about business ownership. This class is a must for anyone considering starting a business!

Monday, May 18, 2015 6–10 p.m.
Saturday, July 11, 2015 9 a.m. – 1 p.m.

For Early Stage Entrepreneurs:

New Venture:

Designed specifically for the entrepreneurs in the early stages of business development.

Wednesdays, June 3–August 5, 2015 6–9 p.m.

For more information, please contact Karen Ambrose, Program Director at 240-567-2592 or e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.

When it comes to the Puget Sound region's biotech industry, is it more important to have big anchor companies or an ever-churning ecosystem of small innovators?

That was one of the questions posed to a panel of three biotech executives last week at an industry forum hosted by news website Xconomy at Fred Hutch.

Don't forget to register NOW for Wednesday's T2 Speakers Series "Commercializing Innovations at Georgetown University" with Georgetown University Office of Technology Commercialization Director Ruchika Nijhara, Ph.D. 

Tech Transfer Speakers Series is a free monthly program offered through the Gateway to Innovation: Montgomery Welcome Center for Federal and Academic Tech Transfer. For more information and additional calendar items, please visit TechTransferConnection.com.  Engage with others in the tech transfer field by joining the Gateway to Innovation LinkedIn Group.  Brought to you by: Montgomery County Department of Economic Development and the Federal Laboratory Consortium for Technology Transfer.

JOIN THE GATEWAY TO INNOVATION LinkedIn Group and start networking with other researchers, federal lab professionals, university technologists, investors, and many others in our area.  Move your technology forward by reaching out and connecting!!

Kelly Chu stands at the front of the room and explains a complex spreadsheet displayed on a projector.

With precision she describes the discounted free cash-flow model she built of a food-services and construction company, and walks through its revenue-growth assumptions before making a recommendation on whether or not to invest.

Free, Open Entrepreneur Office Hours for University of Maryland Students, Faculty and Staff, and Regional Entrepreneurs with Bio or Tech-Based Startups or Ideas  

Get answers now from experienced entrepreneurs and legal/business professionals on how to build a successful startup company. Receive free and impartial advice, brainstorm business strategies, investigate funding opportunities and learn about the vast resources available to entrepreneurs.

There is nothing like the sight of children to inspire hope, so it was only fitting that University of Maryland, Baltimore (UMB) President Jay A. Perman, MD, began his second annual State of the University Address on May 7 with a performance by the sixth-grade dancers from Southwest Baltimore Charter School.

But there was deeper meaning as well to their presence at his optimistic address “Renew the State. Repair the World” before an overflow crowd at the School of Nursing.

Funding and Research Opportunities The following funding opportunity announcements from the NHLBI or other components of the National Institutes of Health, might be of interest: Notices:

• Notice of Chimpanzee Research Use (CRU) Reporting System
• (NOT-OD-15-097) National Institutes of Health
• ASSIST Now an Option for R01 and Individual Career Development Award Applications
• (NOT-OD-15-098) National Institutes of Health
• ASSIST Now an Option for Research Project Cooperative Agreements (U01s) 
• (NOT-OD-15-099) National Institutes of Health

Program Announcements:

• Lasker Clinical Research Scholars Program (Si2/R00)
• (PAR-15-189)
• National Institutes of Health, National Cancer Institute, National Eye Institute, National Human Genome Research Institute, National Heart, Lung, and Blood Institute, National Institute of Allergy and Infectious Diseases, National Institute of Arthritis and Musculoskeletal and Skin Diseases, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institute of Diabetes and Digestive and Kidney Diseases, National Institute of Environmental Health Sciences, National Institute of Mental Health, National Institute of Neurological Disorders and Stroke, National Institute of Nursing Research
• Application Receipt/Submission Date(s): August 27, 2015

Please note that most links to RFAs, PAs, and Guide Notices will take you to the NIH Web site. RFPs will take you to FedBizOpps. Links to RFPs will not work past their proposal receipt date. Archived versions of RFPs posted on FedBizOpps can be found on the FedBizOpps site using the FedBizOpps search function. Under “Document to Search,” select Archived Documents.

Symbiomix Therapeutics today announced multiple milestones, including the closing of the third and final tranche of a $41 million Series A financing and positive results from a multi-center, randomized Phase 2 trial testing a single oral dose of SYM-1219 for the treatment of bacterial vaginosis (BV). Based on discussions with the U.S. Food and Drug Administration (FDA) at an End-of-Phase 2 meeting, the Company now is planning to submit the Phase 2 trial as one of two pivotal studies for a New Drug Application (NDA) filing in 2016. Simultaneously, the Company announced that the FDA recently designated SYM-1219 as a Qualified Infectious Disease Product (QIDP). SYM-1219 is a novel drug candidate that contains secnidazole, an antibiotic with favorable pharmacokinetics that facilitate administration as a single-dose oral therapy.

University of Maryland (UM) Ventures and Biomecite Diagnostics, LLC announced today the signing of an exclusive option by Biomecite Diagnostics for the rights from University of Maryland, Baltimore (UMB) to develop diagnostics to detect inflammatory bowel diseases (IBD), such as ulcerative colitis (UC) and Crohn's disease (CD). Drs. Florian Fricke and James White developed the licensed technology while both were with the University of Maryland School of Medicine's Institute for Genome Sciences (IGS). The technology explores distinctive genomic variances in the populations of bacteria or microbiome found in the human gut to diagnose the closely related but differing gastrointestinal diseases, UC and CD.

Presenter:
Rana Gupta
President, Kwydk, LLC

Moderator:
Gary Robinson, Ph.D.
National Heart, Lung, and Blood Institute

The landscape of potential customers for biomedical products can be complicated, with patients, providers and payers assigning different values to new technologies. Companies must navigate this landscape to find the individuals who will actually make the decision to purchase their products.  In this webinar, entrepreneur and educator Rana Gupta will talk about how customers can not only help biomedical innovators to define the value proposition for their products, but can also guide and fund their product development.

Since it seems that 1776 can’t go a week without making news, they just announced an Innovation Opportunity Program that they are launching with General Assembly. DC’s Mayor Muriel Bowser along with representatives from TDF Foundation, THEARC, Capital One, MedStar Health, and Microsoft were also on hand for the announcement.

Emergent BioSolutions of Gaithersburg has won approval from the U.S. Food and Drug Administration for its hemophilia drug Ixinity.

The treatment, administered intravenously, helps control and prevent bleeding episodes and also is approved for use during surgery in adults and children 12 and older with hemophilia B, according to a company news release. Hemophilia B is a bleeding disorder caused by a mutation on the factor IX gene resulting in a deficiency of clotting factor IX in the blood, which controls bleeding.

On Tuesday, the Senate Health committee held a hearing on the promise of precision medicine. Last week, the House released draft legislation to support biomedical innovation. And following President Obama's State of the Union in January, the White House unveiled the Precision Medicine Initiative, meant to provide funding to accelerate biomedical research.

What none of these things do directly is to curb the price of speciality drugs—including precision drugs—which cost Americans more than $80 billion in 2013, according to the Campaign for Sustainable Rx Pricing.

The Montgomery County Business Hall of Fame will add four new members later this year, including a former space issues attorney turned health company CEO, a bank chairman, a barbecue expert and the chief executive of a hospital.

The following people have been named to the business hall of fame and are scheduled to be honored at an Oct. 27 event:

Photo Credit: Fortune Live Media - Flickr

Drug testing on humans and animals will be a thing of the past within two decades, United Therapeutics CEO Martine Rothblatt said Monday.

Soon, companies will test pharmaceuticals on silicon versions of the human body, entering drugs as code, she said.

Photo Credit: Fortune Live Media - Flickr

The advent of connected devices and M2M is offering a tremendous opportunity for healthcare professionals. Near-ubiquitous mobile networks are allowing carers to diagnose, monitor, and communicate with patients with unprecedented speed and efficacy.

Every venture firm’s looking for many multiples when it comes to returns – but in reality, they expect things to shake out a little differently. Seth DeGroot, a managing partner at boutique Minneapolis investment firm Brightstone Venture Capital, spoke on what the firm’s expectations in potential investment targets – and how startups can avoid pesky problems like, say, overinflated valuations.

NextGen Angels recently announced plans to bring its brand of under-40, entrepreneur-friendly angel investors to 12 more U.S. cities, with plans for international expansion down the line.

I caught up with CEO Dan Mindus, who founded the group in 2012, about both the expansion and the venture market in the Greater Washington area. Based on our conversation, there are two important things about the local funding market that every entrepreneur should probably know:

Gaithersburg-based molecular diagnostics company OpGen Inc. went public Tuesday, and saw its shares drop more than 20 percent during the day before closing at $4.85, down nearly 19 percent.

CEO Evan Jones said he's not concerned. In the world of biotech, making money can take time.

Each time 81-year-old Bill Dworsky or his 80-year-old wife Dorothy opens the refrigerator, closes the bathroom door or lifts the lid on a pill container, tiny sensors in their San Francisco home make notes on a digital logbook.

The couple's 53-year-old son, Phil, checks it daily on his smartphone. If there's no activity during a designated time, the younger Dworsky gets an automated email, so he can decide whether to call or stop by. "This is peace of mind, really," he says of the system he installed last year.

Dr. Patrick Soon-Shiong has some big ideas in healthcare, like a vision of a fully connected ecosystem that truly empowers patients to make informed choices about their own care, aided by supercomputers to crunch all the data, including highly complex genomic information. And he’s not afraid to toot his own horn every once in a while.

“We’ve created the Google of genome mapping,” Soon-Shiong, the multibillionaire entrepreneur behind the still-somewhat-mysterious NantHealth and parent company NantWorks, said Monday at the American Telemedicine Association annual meeting in Los Angeles.

QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) announced today that it has expanded its relationship with BGI, the world's largest genomics organization, to provide QIAGEN's Ingenuity® Variant Analysis™ in integrated bioinformatics for all customers of BGI's sequencing services.

Under the reseller agreement, BGI customers will receive sequencing data generated from their samples through Ingenuity Variant Analysis' secure, cloud-based environment and gain access to its leading comprehensive gene variant data and genomic interpretation applications. BGI will provide Ingenuity Variant Analysis to customers in China, Hong Kong and Taiwan, with plans to expand to other regions throughout the year. BGI collaborates with more than 10,000 organizations and 30,000 partners worldwide, providing sequencing services for thousands of research projects, including large-scale genome initiatives.